The cumulative incidence of ILD following initiation of HER2-directed therapy in the metastatic setting was assessed for 398 patients without prevalent ILD at index whose metastatic disease was diagnosed in 2010 or later. The gene discussed is ERBB2; the disease is metastatic neoplasm.